Clinical Trial Update: Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine [Phase 4]

View source ↗

Summary

Phase 4 trial assessing immunogenicity and safety when coadministering the inactivated SARS-CoV-2 vaccine BBIBP-CorV with the rabies vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rabies

Drugs mentioned

• BBIBP-CorV
• Rabies vaccine (rabies vaccine)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: COVID-19, Rabies | Phase 4 | Status: UNKNOWN